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Abstract
Background: Head fixation can induce hemodynamic instability. Remifentanil is commonly used with propofol for
total intravenous anesthesia (TIVA) during neurosurgery. This study investigated the 90% effective concentration
(EC90) of remifentanil for blunting of cardiovascular responses to head fixation during neurosurgery via bispectral
index (BIS) monitoring.
Methods: Fifty patients undergoing neurosurgery requiring head fixation were enrolled. This study was performed
using the biased coin up-and-down design sequential method (BCD). After tracheal intubation, the effect-site target
concentration (Ce) of remifentanil was adjusted to achieve hemodynamic stability and reset to the level
preoperatively assigned to each patient, according to the BCD method, approximately 10 min before head fixation.
Baseline hemodynamic values were recorded before head fixation. An ineffective response was defined as a case
with a > 20% increase in hemodynamic values from baseline. Otherwise, the response was determined to be
effective. The EC90 of remifentanil was calculated as a modified isotonic estimator.
Results: Forty-three patients completed this study. The EC90 of remifentanil for blunting cardiovascular responses to
head fixation was estimated to be 6.48 ng/mL (95% CI, 5.94–6.83 ng/mL).
Conclusions: Adjustment of the Ce of remifentanil to approximately 6.5 ng/mL before head fixation could prevent
noxious cardiovascular responses in 90% of neurosurgical ASA I-II patients aged 20 to 65 years old during propofol
target-controlled infusion titrated to maintain BIS between 40 and 50.
Trial registration: ClinicalTrials.gov Identifier NCT01489137, retrospectively registered 5 December 2011.
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Background
A head holder is commonly used to stabilize the head dur-
ing neurosurgery. Skull pin insertion, head pinning, and
pin fixation are synonyms for head fixation and indicate
the application of a head holder. Use of a head holder is of
paramount importance during stereotactic neurosurgery.
However, anesthesiologists may encounter hemodynamic
changes that require pharmacological intervention due to
a noxious stimulus resulting from head fixation. Acute ar-
terial hypertension can lead to intracranial hemorrhage [1,
2]. Therefore, various strategies have been used to reduce
the degree of hemodynamic changes induced by head fix-
ation, resulting in various recommendations [3–7].
Recently, total intravenous anesthesia (TIVA) has
become a widely used method for general anesthesia.
Among various combinations of intravenous anesthetics,
continuous propofol infusion and opioid supplementation
is a widely used combination. TIVA is considered a stand-
ard method of general anesthesia, especially for evoked
potential monitoring [8]. Due to its pharmacodynamic
and pharmacokinetic characteristics, such as a very short
context-sensitive half-time and minimal effects on cardio-
vascular system, remifentanil is a commonly used opioid
in conjunction with propofol for TIVA.
This study was designed to estimate the 90% effective
concentration (EC90) of remifentanil for blunting cardio-
vascular responses to head fixation during neurosurgery
under TIVA with bispectral index (BIS) monitoring.
Methods
This study was approved by the Institutional Review
Board of the Seoul National University Hospital. Written
informed consent was obtained from all patients. The trial
was registered at www.clinicaltrials.gov (NCT01489137).
American Society of Anesthesiologists physical status I-II
patients were enrolled in this study. The patients were
20–65 years old and were scheduled to undergo elective
neurosurgery requiring head fixation. Patients who were
obese (body mass index >30.0) or severely underweight
(body mass index <16.0), had hypertension, cardiac dis-
ease, pulmonary disease, or renal disease, used current
medication affecting the cardiovascular system, or were
addicted to substances or alcohol were excluded from this
study. Furthermore, patients who were administered any
drugs that affect the cardiovascular system, such as ephe-
drine, during the period from the induction of anesthesia
to head fixation were excluded.
Anesthesia
Prior to the surgery, patients fasted for 8 h and received
no premedication. A standard monitoring and anesthetic
technique was applied to all patients in the operating
room. All patients received TIVA with propofol and
remifentanil using a target-controlled infusion (TCI)
system under BIS monitoring with the BIS VISTA™
system (Aspect Medical Systems, Newton, MA, USA).
The Schnider and Minto models were selected as the
pharmacokinetic models for propofol and remifentanil,
respectively [9, 10]. The TCI mode was set to the effect-
site control using an Orchestra™ device (Fresenius Vial,
France).
The same effect-site target concentrations (Ce) of
propofol (4 μg/mL) and remifentanil (4 ng/mL) were
given to all patients for anesthetic induction. After
induction of anesthesia, the lungs of patients were venti-
lated via manual bagging, and 0.8 mg/kg rocuronium was
administered. After muscle relaxation, an anesthesiologist
inserted a 20-G catheter into the radial artery to monitor
continuous arterial blood pressure during the operation.
Then, tracheal intubation was performed. Infusion of 0.9%
normal saline (10 mL/kg) was performed during the
trial to compensate for dehydration from overnight
fasting, which was completed before recording baseline
hemodynamics.
Study design and setting
At approximately 10 min before head fixation, the
propofol Ce was adjusted to maintain the BIS at ap-
proximately early 40s, but over than 40. During the re-
mainder of the operation, the propofol Ce was adjusted
to maintain the BIS at between 40 and 50. After endo-
tracheal intubation, the remifentanil Ce was adjusted to
stabilize the hemodynamic responses. The remifentanil
Ce was reset to the preoperatively assigned level at least
10 min before the initiation of head fixation. This was
performed by the same anesthesiologist in each case:
the anesthesiologist opened an envelope containing a
card stating the remifentanil Ce assigned to the patient
and then adjusted the Ce to the assigned level by
modulating the TCI pump for the patient. A second,
standing anesthesiologist managed the patient for the
whole operation and recorded the vital signs during
head fixation. The standing anesthesiologist was
blinded to the remifentanil Ce by covering the screen
of the Orchestra™ device with a sheet of paper during the
study. Before the study, the standing anesthesiologist was
ordered to only administer vasoactive drugs such as ephe-
drine in cases in which the mean arterial blood pressure
(MAP) decreased to <55 mmHg before head fixation. The
MAP and heart rate (HR) were recorded by a standing
anesthesiologist at 1 and 2 min before head fixation, and
the means of these readings were calculated and used as
the baseline values (MAPBL and HRBL). Neurosurgeons
performed head fixation without any local infiltration of
anesthetics at the pin site or use of a scalp nerve block.
The MAP and HR were monitored and recorded during
head fixation and the immediate post-fixation period.
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The peak values during head fixation were recorded to
determine their primary end-points, which were defined
as the percentage increases compared to the MAPBL and
HRBL ([peak value – baseline]/baseline × 100%). After
completion of head fixation, the MAP and HR were ob-
served for 5 min, and the values were recorded each mi-
nute. Figure 1 shows the timeline of the study.
A vasoactive drug or β-agonist was prepared for
administration if the MAP decreased to <55 mmHg or
the HR decreased to <45/min. Subjects who were admin-
istered these drugs before head fixation were excluded
from the study. We were also prepared to inject appropri-
ate drugs if the MAP and HR did not return to within
120% of baseline values within 3 min after head fixation.
Statistical analyses
The EC90 of remifentanil that attenuated the cardiovas-
cular responses to head fixation was estimated using the
biased coin up-and-down design sequential method
(BCD) [11]. The remifentanil Ce for the first subject was
set to 5.5 ng/mL based on our past clinical experience.
The remifentanil Ce for the next patient was determined
by the responses of the previous subject who had com-
pleted the trial; a Ce difference of 0.5 ng/mL was chosen
as our step size. In case of failure to attenuate the
hemodynamic responses to head fixation, (> 20% in-
crease in MAPBL or HRBL), the following subject would
receive a higher Ce at an increment of 0.5 ng/mL. If the
change was within a 20% increase for both the MAPBL
and HRBL (thus, the remifentanil Ce was effective), the
remifentanil Ce for the next subject was randomly
assigned with a probability of 0.89 (8/9) of a Ce decre-
ment of 0.5 ng/mL from the prior subject’s Ce or a prob-
ability of 0.11 (1/9) of the same Ce as the prior subject.
If a subject was excluded for any reason, the subsequent
subject was given the Ce assigned to the excluded
subject.
A sample size of at least 40 was determined according
to a statistical reference [12]. The EC90 was estimated by
calculating a modified isotonic estimator (MIE) [12].
The R 2.14.1 program (R foundation for Statistical Com-
puting, Vienna, Austria) was used for this calculation.
The 95% confidence interval (CI) was obtained using a
parametric bootstrap routine and calculated by a bias-
corrected percentile method [11].
Results
Fifty patients were enrolled in the study. Seven patients
were excluded due to the use of ephedrine to treat
hypotension prior to head fixation (n = 4), inadequate
steady-state time (< 10 min) from reset of the remifentanil
Ce to head fixation (n = 2), and topical infiltration of 1%
lidocaine with epinephrine (1:200,000) for nasal mucosa
vasoconstriction prior to head fixation in a tumorectomy
with a trans-sphenoidal approach (n = 1).
A total of 43 patients completed this study, and their
data were analyzed. The remifentanil Ce ranged from 5.0
to 7.0 ng/mL according to the BCD method (Fig. 2).
The patients’ clinical characteristics are listed in
Table 1. Among the 43 subjects who completed the
study, seven experienced hemodynamic changes char-
acterized by a > 20% increase in their MAPBL or HRBL
values. Thus, the remifentanil Ce used in these subjects
was not sufficient to alleviate their hemodynamic re-
sponses to head fixation. Although these were recorded
as failures, the severity of the change was not sufficient
to require antihypertensive drugs. The hemodynamic
changes in the remaining subjects were characterized
by ≤20% increases from baseline values, and these were
considered effective cases. In all cases, the MAP and
HR returned to within 120% of the baseline value
within 2 and 1 min, respectively.
The BIS of 42 of the 43 subjects increased. The change
in the BIS among all 43 subjects was 6.6 ± 3.0 (mean ± SD).
The BIS decreased by only 1 in one subject.
The calculated EC90 of remifentanil was 6.48 ng/mL
(95% CI, 5.96–6.83 ng/mL). Figure 3 shows changes in
the MAP and HR in subjects with remifentanil Ce values
of 6.0 (n = 10), 6.5 (n = 21), and 7.0 ng/mL (n = 5),
which were similar to the EC90 calculated using our
Fig. 1 Timeline of the study. ▼, recording point of hemodynamic parameters
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results. We also calculated the EC50 (5.33 ng/mL; 95%
CI, 5.27–5.44 ng/mL) and EC95 (6.74 ng/mL; 95% CI,
6.28–6.93 ng/mL).
Discussion
In this study, the EC90 of remifentanil was calculated as
6.48 ng/mL (95% CI, 5.96–6.83 ng/mL). This Ce is
approximately 20% higher than that typically used in our
hospital (5.5 ng/mL).
Previously, several studies have investigated the most
effective method of alleviating hemodynamic responses to
head fixation [3–7]. The authors introduced and com-
pared various strategies, such as intravenous opioids, local
anesthetic infiltration at the pin sites, a combination of
intravenous fentanyl and local anesthetic infiltration, and
scalp nerve blockade. However, no consensus exists to
guide anesthesiologists in attenuating cardiovascular re-
sponses to head fixation. In our experience, intravenous
fentanyl injection alone may not be sufficiently effective in
many cases, and local anesthetic infiltration may not al-
ways be effective because sometimes the exact pin sites
may not match the infiltrated scalp area. Furthermore, in
some cases, surgeons reposition the skull pins after their
first attempt at head fixation. We perform scalp nerve
blockade as a routine practice in patients undergoing
awake craniotomy. In our experience, the effect of scalp
nerve blockade is usually highly potent. A previous study
showed an approximately 6.8% increase in the MAP from
the MAPBL due to head fixation in patients who received
scalp nerve block with bupivacaine [7]. In our study, the
increase in MAP in patients with a remifentanil Ce of
6.5 ng/mL was approximately 12.3%. However, scalp nerve
block is not always effective, and its performance requires
extra time and training.
As mentioned previously, remifentanil has excellent
characteristics and is commonly used, along with pro-
pofol, by anesthesiologists for TIVA with a TCI system
during neurosurgery. If a remifentanil Ce that effect-
ively reduces hemodynamic responses to head fixation
is attained, the anesthesiologists can maintain a stable
hemodynamic status with fewer drugs and use a sim-
pler approach.
Recently, a similar study was conducted to determine
the EC50 of remifentanil necessary to minimize the car-
diovascular changes due to head fixation under TIVA
with BIS monitoring [13]. The authors in that study used
the Dixon up-and-down sequential allocation method.
They found that the EC50 of remifentanil was 2.90 ng/
mL (95% CI, 1.78–3.65 ng/mL) and showed that the
EC95 was 4.28 ng/mL (95% CI, 3.85–4.41 ng/mL) via
isotonic regression estimation. These values were lower
than our results.
Several differences existed between their study and
ours. First, we used the BCD method, but they used the
Dixon up-and-down method (UDM). Second, while we
defined the MAPBL and HRBL values as the levels
observed during the steady state at 1–2 min before the
head fixation, they defined the baseline values as the
levels observed before induction of anesthesia. Third, we
adjusted the propofol Ce based on the BIS in our study,
but they fixed the propofol Ce during the trial.
We used the BCD method to determine the EC90 of
remifentanil for alleviation of cardiovascular responses
due to head fixation. Many preliminary studies have
used the UDM of Dixon and Mood to determine the
ED50/EC50. The UDM was designed to estimate the
median threshold, including the ED50 or EC50 [11, 14].
Although it would be possible to estimate the ED90/EC90
or ED95/EC95 by extrapolation in a UDM study, extrapo-
lation of a high-quantile effect dose/concentration from
the tolerance distribution curve determined by the UDM
is not adequate due to weak precision [11]. Therefore,
Fig. 2 Remifentanil Ce assignment and patient responses. The
remifentanil Ce for the first subject was 5.5 ng/mL. The Ce assigned
to sequential subjects was determined by the biased coin design
up-and-down sequential method. Ce, effect-site target concentration
Table 1 Clinical characteristics of the 43 subjects who completed
the study
Variables Mean ± SD
Males / females (n) 20a / 23a
Age (y) 46.6 ± 11.0
Weight (kg) 64.1 ± 11.2
Height (cm) 163.5 ± 9.1
BMI (kg/m2) 23.9 ± 3.1
Ce of Propofol during fixation (μg/mL) 2.9 ± 0.7
BIS prior to fixation 41.2 ± 2.0
Baseline MAP (mmHg) 77.4 ± 11.7
Baseline HR (beats/min) 61.7 ± 9.8
BMI body mass index. Ce, effect-site target concentration. The results are
presented as the mean ± SD or numbersa
Lee et al. BMC Anesthesiology  (2017) 17:136 Page 4 of 7
the BCD method is more suitable for determining the
high-quantile effect dose/concentration because a BCD
study can be performed to target the EC90, permitting a
direct estimation of the EC90 and avoiding unverifiable
extrapolations from the EC50 value [11]. Although, the
EC95 would be more attractive to clinicians, a previous
study showed that a sample size of 40 resulted in signifi-
cantly less precision than determination of the EC90
using a simulation test [15]. Therefore, we determined
the EC90 using the BCD method with a sample size of
about 40.
We used the MAP and HR values 1–2 min before head
fixation as baseline hemodynamic values. In neurosurgery
on the brain, acute arterial hypertension may induce intra-
cranial hypertension in patients with intracranial tumors
and peritumoral edema [16]. In addition, a previous study
reported that intracranial pressure could be rapidly in-
creased by head fixation in patients with a brain tumor
[2]. So, we used these values as baseline values of MAP
and HR because we thought it should be important to
prevent the abrupt increase of hemodynamics due to head
fixation.
In the present study, we aimed to maintain BIS values
at between 40 and 50 during the operative period and at
approximately early 40s, but ≥40, immediately before
head fixation. BIS values between 40 and 60 are recom-
mended as an adequate level for general anesthesia in
several studies [17, 18]. Another recommendation states
that the BIS should be greater than 45 because BIS
values below 45 are associated with increased mortality
[19–22]. Sessler et al. introduced the ‘Triple low’ concept
(low minimum alveolar concentration (MAC), low MAP,
and low BIS), which was a strong and highly statistically
significant predictor of mortality [23]. However, the au-
thors of the study interpreted the finding to indicate
that high-risk patients were sensitive to anesthetics
rather than as an indication that the ‘Triple low’ (low
MAC, low MAP, and low BIS) was a causative factor of
high mortality. Several previous studies have supported
Sessler’s study [22, 24, 25]. However, some studies have
also provided conflicting results on this issue [26, 27].
A recent study found that a “smart alarm” to indicate
the ‘Double low’ (low MAP <75 mmHg and a low BIS
<45) did not decrease mortality [28]. Moreover, we
found that the 30-day, 90-day, 1-year, and 5-year mor-
tality rates were 0/43, 1/43, 3/43, and 3/43, respectively,
in our study. This result is comparable to previous
studies, even with the small sample size of our study
[22, 28, 29].
A previous study reported that a BIS value between 50
and 60 prior to tracheal intubation was inadequate to pre-
vent an awareness reaction to tracheal intubation during
propofol/alfentanil anesthesia, although no recall case was
included in that study [30]. In addition, two case reports
and one randomized controlled trial presented awareness
reactions despite use of the recommended BIS level, 40–
60 [31, 32]. Therefore, we maintained the BIS between 40
and 50 during whole operation, and a target BIS value
near 40 (but ≥40) was used just before head fixation to
avoid awareness.
Fig. 3 Changes in the mean arterial blood pressure and heart rate of subjects with remifentanil Ce values of 6.0 (n = 10), 6.5 (n = 21) and 7.0
(n = 5) ng/mL. The Y axis in all figures [(a) to (f)] represents the ratio of hemodynamic parameters to baseline values. The X axis represents the
time-points at which hemodynamic parameters were recorded. a, b, and c show the arterial blood pressure ratio compared to baseline values
in patients assigned to a remifentanil Ce of 6.0, 6.5 and 7.0 ng/mL, respectively. d, e, and f show the heart rate ratio compared to baseline
values in patients assigned to a remifentanil Ce of 6.0, 6.5 and 7.0 ng/mL, respectively. BV indicates the baseline values of hemodynamic
parameters; PV indicates peak value of hemodynamic parameters immediately after head fixation; Ce is the effect-site target concentration;
the numbers 1, 2, 3, 4 and 5 on the X-axis represent the time (min) after fixation
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No patients experienced bradycardia (HR < 45) in this
study. However, four subjects experienced hypotension
with an MAP of <55 mmHg and were administered ephe-
drine. The incidence of hypotension resulting from the
use of a remifentanil Ce of 6.5 ng/mL in this study was
8.7% (2/23). Based on our experience, hypotension is not
uncommon during neurosurgery using this anesthetic
technique.
A limitation of our study was that the subjects did
not represent the entire group of patients who required
head fixation for craniotomy. Twenty-seven patients
were excluded prior to consent due to a diagnosis of
hypertension during the pre-assessment. These subjects
were excluded because patients with chronic hyperten-
sion can show an exaggerated response to noxious
stimulation [33]. Further research into safer use of
remifentanil in a more heterogeneous patient popula-
tion with an unstable hemodynamic status, such as
hypertension, is needed. A combination of propofol and
remifentanil anesthesia using TCI with local anesthetic
injection at the pin site or scalp nerve blockade might
be an appropriate strategy for patients with an unstable
hemodynamic status. Remifentanil Ce values that are
lower than that calculated in the present study (6.5 ng/
mL) may be needed to maintain stable vital signs in pa-
tients receiving a combination of TIVA with local injec-
tion, scalp nerve block or any premedication; this should
be verified in future studies. We determined that an EC90
of remifentanil of 6.5 ng/mL is necessary to alleviate
hemodynamic instability caused by head fixation in a
small sample of patients (n = 43) using the BCD method.
However, this sample size is not sufficient to generalize
our results to all patients requiring head fixation. There-
fore, further studies are needed to validate our results.
Conclusions
Adjustment of the remifentanil Ce to approximately
6.5 ng/mL before head fixation could prevent noxious
cardiovascular responses in 90% of neurosurgical ASA
I-II patients aged 20 to 65 years old during propofol
TCI titrated to maintain BIS between 40 and 50.
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